1340593-92-1

Basic information

• Product Name: C₂₂H₁₄F₇NO₂
• Synonyms: C₂₂H₁₄F₇NO₂
• CAS NO: 1340593-92-1
• Molecular Weight: 457.347
• Mol File: 1340593-92-1.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: C₂₂H₁₄F₇NO₂(CAS DataBase Reference)
• NIST Chemistry Reference: C₂₂H₁₄F₇NO₂(1340593-92-1)
• EPA Substance Registry System: C₂₂H₁₄F₇NO₂(1340593-92-1)

Safety Data

• Hazardous Substances Data: 1340593-92-1(Hazardous Substances Data)

Upstream product

• 294182-06-2 2-(5-bromopyridin-2-yl)-1-(2,4-difluorophenyl)-2,2-difluoroethanone 
• 886536-37-4 (4-(2,2,2-trifluoroethoxy)phenyl)boronic acid 
• 294182-28-8 5-bromo-2-((-2-(2,4-difluorophenyl)oxiran-2-yl)difluoromethyl)pyridine 
• 294181-95-6 2-(5-bromopyridine-2-yl)-2,2-difluoroacetic acid ethyl ester 
• 624-28-2 2,5-dibromopyridine 

Downstream Products

• 1340593-59-0 2-(2,4-difluorophenyl)-1,1-difluoro-3-(1H-tetrazol-1-yl)-1-(5-(4-(2,2,2-trifluoroethoxy)phenyl)pyridin-2-yl)propan-2-ol 
• 1340593-59-0 (2R)-2-(2,4-difluorophenyl)-1,1-difluoro-3-(1H-1,2,3,4-tetrazol-1-yl)-1-{5-[4-(2,2,2-trifluoroethoxy)phenyl]pyridin-2-yl}propan-2-ol 

Relevant articles and documents

Fungal lanosterol 14α-demethylase (CYP51) inhibitor Treatment of recurrent vulvovaginal candidiasis Treatment of onychomycosis

Developing a rationally designed, more selective azole antifungal agent that specifically targets the fungal CYP51 over the host CYP51 is a severe unmet need considering a massive shortfall in novel antifungal agents. In this context, oteseconazole (VT-1161) represents a very exciting new development targeting serious fungal infections caused by a wide variety of fungal pathogens including multidrug-resistant Candida responsible for recurrent vulvovaginal candidiasis. This monograph details the various in vitro and in vivo properties exhibited by oteseconazole as well as its current status in clinical trials.

METALLOENZYME INHIBITOR COMPOUNDS

The instant invention describes compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.